Tuesday, May 30, 2023


Biotechnology News Magazine


Oxford Properties Invests in Cambridge to Extend Global Life Sciences Platform with 1st European Acquisition

With the acquisition of 310 Cambridge Science Park Oxford has committed US$1.3 billion to life sciences in 2021.

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries

Enveric aims to move into the clinic with novel cannabinoid and psychedelic-derived therapies to improve standard of care and serve unmet needs across multiple indications including oncology and CNS, such as PTSD.

New England Biolabs® to Acquire Fluorogenics Limited

"The acquisition of FGL enables NEB to combine our expertise in enzyme manufacturing and assay development with their expertise in lyophilization, providing a complete solution for our customers," states Jim Ellard, CEO of New England Biolabs.

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses.

Grünenthal Acquires Mestex AG

Grünenthal advises Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee.

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

Sumit Aggarwal, previously the President and Chief Executive Officer of Zikani, has been named President and Chief Executive Officer of Eloxx, and Vijay Modur, M.D., Ph.D., who was Zikani’s Chief Scientific and Medical Officer, has been named Eloxx’s Head of Research and Development.